Anti-HDV IgM as a marker of disease activity in hepatitis delta.
Hepatitis delta frequently leads to liver cirrhosis and hepatic decompensation. As treatment options are limited, there is a need for biomarkers to determine disease activity and to predict the risk of disease progression. We hypothesized that anti-HDV IgM could represent such a marker.Samples of 12...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4114528?pdf=render |
| _version_ | 1819209167064268800 |
|---|---|
| author | Anika Wranke Benjamin Heidrich Stefanie Ernst Beatriz Calle Serrano Florin Alexandru Caruntu Manuela Gabriela Curescu Kendal Yalcin Selim Gürel Stefan Zeuzem Andreas Erhardt Stefan Lüth George V Papatheodoridis Birgit Bremer Judith Stift Jan Grabowski Janina Kirschner Kerstin Port Markus Cornberg Christine S Falk Hans-Peter Dienes Svenja Hardtke Michael P Manns Cihan Yurdaydin Heiner Wedemeyer HIDIT-2 Study Group |
| author_facet | Anika Wranke Benjamin Heidrich Stefanie Ernst Beatriz Calle Serrano Florin Alexandru Caruntu Manuela Gabriela Curescu Kendal Yalcin Selim Gürel Stefan Zeuzem Andreas Erhardt Stefan Lüth George V Papatheodoridis Birgit Bremer Judith Stift Jan Grabowski Janina Kirschner Kerstin Port Markus Cornberg Christine S Falk Hans-Peter Dienes Svenja Hardtke Michael P Manns Cihan Yurdaydin Heiner Wedemeyer HIDIT-2 Study Group |
| author_sort | Anika Wranke |
| collection | DOAJ |
| description | Hepatitis delta frequently leads to liver cirrhosis and hepatic decompensation. As treatment options are limited, there is a need for biomarkers to determine disease activity and to predict the risk of disease progression. We hypothesized that anti-HDV IgM could represent such a marker.Samples of 120 HDV-infected patients recruited in an international multicenter treatment trial (HIDIT-2) were studied. Anti-HDV IgM testing was performed using ETI-DELTA-IGMK-2-assay (DiaSorin). In addition, fifty cytokines, chemokines and angiogenetic factors were measured using multiplex technology (Bio-Plex System). A second independent cohort of 78 patients was studied for the development of liver-related clinical endpoints (decompensation, HCC, liver transplantation or death; median follow up of 3.0 years, range 0.6-12).Anti-HDV IgM serum levels were negative in 18 (15%), low (OD<0.5) in 76 (63%), and high in 26 (22%) patients of the HIDIT-2 cohort. Anti-HDV IgM were significantly associated with histological inflammatory (p<0.01) and biochemical disease activity (ALT, AST p<0.01). HDV replication was independent from anti-HDV IgM, however, low HBV-DNA levels were observed in groups with higher anti-HDV IgM levels (p<0.01). While high IP-10 (CXCL10) levels were seen in greater groups of anti-HDV IgM levels, various other antiviral cytokines were negatively associated with anti-HDV IgM. Associations between anti-HDV IgM and ALT, AST, HBV-DNA were confirmed in the independent cohort. Clinical endpoints occurred in 26 anti-HDV IgM positive patients (39%) but in only one anti-HDV IgM negative individual (9%; p = 0.05).Serum anti-HDV IgM is a robust, easy-to-apply and relatively cheap marker to determine disease activity in hepatitis delta which has prognostic implications. High anti-HDV IgM levels may indicate an activated interferon system but exhausted antiviral immunity. |
| first_indexed | 2024-12-23T05:50:58Z |
| format | Article |
| id | doaj.art-37e9e3e2e8ec4160824f875cfb67f7bd |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-23T05:50:58Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-37e9e3e2e8ec4160824f875cfb67f7bd2022-12-21T17:57:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0197e10100210.1371/journal.pone.0101002Anti-HDV IgM as a marker of disease activity in hepatitis delta.Anika WrankeBenjamin HeidrichStefanie ErnstBeatriz Calle SerranoFlorin Alexandru CaruntuManuela Gabriela CurescuKendal YalcinSelim GürelStefan ZeuzemAndreas ErhardtStefan LüthGeorge V PapatheodoridisBirgit BremerJudith StiftJan GrabowskiJanina KirschnerKerstin PortMarkus CornbergChristine S FalkHans-Peter DienesSvenja HardtkeMichael P MannsCihan YurdaydinHeiner WedemeyerHIDIT-2 Study GroupHepatitis delta frequently leads to liver cirrhosis and hepatic decompensation. As treatment options are limited, there is a need for biomarkers to determine disease activity and to predict the risk of disease progression. We hypothesized that anti-HDV IgM could represent such a marker.Samples of 120 HDV-infected patients recruited in an international multicenter treatment trial (HIDIT-2) were studied. Anti-HDV IgM testing was performed using ETI-DELTA-IGMK-2-assay (DiaSorin). In addition, fifty cytokines, chemokines and angiogenetic factors were measured using multiplex technology (Bio-Plex System). A second independent cohort of 78 patients was studied for the development of liver-related clinical endpoints (decompensation, HCC, liver transplantation or death; median follow up of 3.0 years, range 0.6-12).Anti-HDV IgM serum levels were negative in 18 (15%), low (OD<0.5) in 76 (63%), and high in 26 (22%) patients of the HIDIT-2 cohort. Anti-HDV IgM were significantly associated with histological inflammatory (p<0.01) and biochemical disease activity (ALT, AST p<0.01). HDV replication was independent from anti-HDV IgM, however, low HBV-DNA levels were observed in groups with higher anti-HDV IgM levels (p<0.01). While high IP-10 (CXCL10) levels were seen in greater groups of anti-HDV IgM levels, various other antiviral cytokines were negatively associated with anti-HDV IgM. Associations between anti-HDV IgM and ALT, AST, HBV-DNA were confirmed in the independent cohort. Clinical endpoints occurred in 26 anti-HDV IgM positive patients (39%) but in only one anti-HDV IgM negative individual (9%; p = 0.05).Serum anti-HDV IgM is a robust, easy-to-apply and relatively cheap marker to determine disease activity in hepatitis delta which has prognostic implications. High anti-HDV IgM levels may indicate an activated interferon system but exhausted antiviral immunity.http://europepmc.org/articles/PMC4114528?pdf=render |
| spellingShingle | Anika Wranke Benjamin Heidrich Stefanie Ernst Beatriz Calle Serrano Florin Alexandru Caruntu Manuela Gabriela Curescu Kendal Yalcin Selim Gürel Stefan Zeuzem Andreas Erhardt Stefan Lüth George V Papatheodoridis Birgit Bremer Judith Stift Jan Grabowski Janina Kirschner Kerstin Port Markus Cornberg Christine S Falk Hans-Peter Dienes Svenja Hardtke Michael P Manns Cihan Yurdaydin Heiner Wedemeyer HIDIT-2 Study Group Anti-HDV IgM as a marker of disease activity in hepatitis delta. PLoS ONE |
| title | Anti-HDV IgM as a marker of disease activity in hepatitis delta. |
| title_full | Anti-HDV IgM as a marker of disease activity in hepatitis delta. |
| title_fullStr | Anti-HDV IgM as a marker of disease activity in hepatitis delta. |
| title_full_unstemmed | Anti-HDV IgM as a marker of disease activity in hepatitis delta. |
| title_short | Anti-HDV IgM as a marker of disease activity in hepatitis delta. |
| title_sort | anti hdv igm as a marker of disease activity in hepatitis delta |
| url | http://europepmc.org/articles/PMC4114528?pdf=render |
| work_keys_str_mv | AT anikawranke antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT benjaminheidrich antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT stefanieernst antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT beatrizcalleserrano antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT florinalexandrucaruntu antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT manuelagabrielacurescu antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT kendalyalcin antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT selimgurel antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT stefanzeuzem antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT andreaserhardt antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT stefanluth antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT georgevpapatheodoridis antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT birgitbremer antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT judithstift antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT jangrabowski antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT janinakirschner antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT kerstinport antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT markuscornberg antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT christinesfalk antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT hanspeterdienes antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT svenjahardtke antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT michaelpmanns antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT cihanyurdaydin antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT heinerwedemeyer antihdvigmasamarkerofdiseaseactivityinhepatitisdelta AT hidit2studygroup antihdvigmasamarkerofdiseaseactivityinhepatitisdelta |